← Evidence map

ArticleEuropean journal of haematology2026

KRAS Mutations Predict Inferior Post-Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations.

Kensuke Takaoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

KRAS Mutations Predict Inferior Post-Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations. | OpenQuestion